Browse our collection of papers in
Astrazeneca (AZN)
C/B/587. AstraZeneca: Strategy Evaluation
- WORDS:
- 1400
- DATE:
- 2007
- PRICE:
- 19.99 GBP
AstraZeneca Plc, a leading global pharmaceutical company, specialises in cardiovascular, gastrointestinal, infection, neuroscience, oncological and respiratory therapies. AstraZeneca's key products such as Nexium, Seroquel, Crestor, Arimidex, and Symbicort achieved good sales growth for the third quarter of 2006 in a highly competitive drug making sector. Yet the Company's global sales ranks fourth behind GlaxoSmithKline, Sanofi-Aventis and Novartis. Issues raised in this report denotes a critical dimension that may weaken or strengthen AstraZeneca's position in taking advantage of the opportunities occurring and key developments expected in the pharmaceutical industry in five years from now.
KEYWORDS: AstraZeneca, Strategy, Pharmaceutical Industry, Drug Prescription Sector,
Subject Catalogue
- Dissertations and Proposals
- Analysis of Companies
- Analysis of Industries
- Architecture, Design and Technology
- Computing and Mathematics
- E-Commerce and E-Business
- Economics
- Education
- Engineering
- Fashion and Culture
- Finance and Accounting
- General Business
- History
- Hospitality and Tourism
- Human Resource Management
- International Relations
- Law
- Literature, Language and Theatre Studies
- Management and Organisational Behaviour
- Marketing
- Media, Music and Art
- Operations Management
- Philosophy
- Politics
- Psychology
- Science, Medicine and Nursing
- Sociology
Keywords Tag Cloud
GET OUR GooGLE TOOLBAR BUTTON
BOOK MARK US
WHAT OTHERS HAVE SAID
Paper received thanks. I was pleased with the speed of processing the order.James M
